JP Morgan Chase’s Zhengye Biotechnology Holding ZYBT Stock Holding History

JP Morgan Chase’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93	Buy	+134	New	+$120	﹤0.01%	7543
2026 Q1	–	Sell	-457	Closed	-$526	–	8019
2025 Q4	$526	Buy	+457	New	+$1.01K	﹤0.01%	7078

Other funds holding ZYBT

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

JP Morgan Chase's ZYBT Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Zhengye Biotechnology Holding (ZYBT) in Q2 2026: 134 shares worth $93. The stake represents ﹤0.01% of the portfolio and ranks #7543 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in ZYBT as recently as Q4 2025.

JP Morgan Chase first reported a position in ZYBT in Q4 2025 and has held it in 2 quarters since. The position peaked at $526 in Q4 2025. 6 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

JP Morgan Chase held 134 shares of Zhengye Biotechnology Holding worth $93 as of Q2 2026.
Zhengye Biotechnology Holding was a new JP Morgan Chase position in Q2 2026.
Zhengye Biotechnology Holding made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7543 holding.
JP Morgan Chase first reported a position in Zhengye Biotechnology Holding in Q4 2025 and has held it in 2 quarters since.
JP Morgan Chase's Zhengye Biotechnology Holding position peaked at $526 in Q4 2025.
6 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.